Stopping PCP is not like stopping alcohol or opioids, and the honest reason is narrower than it sounds. Neither NIDA’s page on hallucinogens and dissociative drugs [2] nor the StatPearls review of phencyclidine toxicity [1] describes a distinct physical withdrawal syndrome for PCP. What the literature does describe is different and, for a lot of people, more unsettling: symptoms that come back in waves long after the last use, because of how the drug is stored in the body [1].
That single fact changes what a plan has to cover. It is why “how long until this is over” has no clean answer, and why the plan matters more than the calendar.
This page sets out what is known and what is not: whether stopping is dangerous, which symptoms show up and in which body systems, how the first weeks tend to run, what makes one person’s experience harder than another’s, what a supervised setting adds, and what treatment looks like afterwards. Our page on what PCP is and how it is used covers the drug itself; this one covers stopping, and it sits inside our wider guide to drug addiction.
Is stopping PCP dangerous?
The danger sits somewhere different from where people expect it. For alcohol and for sedatives, the act of stopping is itself the medical emergency. For PCP, the documented emergencies are attached to intoxication and to the psychiatric effects rather than to a withdrawal syndrome.
StatPearls names rhabdomyolysis, hypoglycemia, seizures, hypertensive crisis, coma and trauma as several of the complications that can arise with PCP use [1]. Those are consequences of being under the influence, not of stopping, and they are the reason emergency departments see PCP at all.
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.
The second risk is psychiatric. PCP can cause psychosis that persists for days to weeks [2]. Research suggests it can also make symptoms worse in people who have schizophrenia, and that hedge is NIDA’s own [2]. A period of confusion or paranoia after the drug itself is gone is a recognized picture, not an imagined one.
The third risk is the one nobody plans for: what else is in the picture. Very few people who use PCP use only PCP, and if alcohol or a sedative is also part of the pattern, then the dangerous withdrawal rules for those substances apply in full. That is a question for an assessment rather than for a web page. Our overview of withdrawal symptoms across substances sets out where the medical risk is concentrated.
None of that makes stopping on your own a good idea. It means the reason to have a clinician involved is different from the alcohol reason.
PCP withdrawal symptoms, grouped by system
Neither of the two clinical sources this page rests on gives a symptom checklist for PCP cessation the way federal material does for alcohol or opioids. NIDA’s page on hallucinogens and dissociative drugs does not [2], and neither does the StatPearls review of phencyclidine toxicity [1]. So the honest way to group what people report is by the body system the published clinical material actually addresses.
Neurological and cognitive. This is where the literature is clearest. PCP is fat-soluble and can be released from lipid stores and adipose tissue, which produces recurrent, fluctuating symptoms that can occur days to months after the initial use [1]. In practice that means episodes of disorientation, nystagmus or unsteadiness can reappear without a new exposure.
Psychiatric. NIDA says PCP can cause psychosis that persists for days to weeks [2]. Anxiety, agitation and mood disturbance commonly sit alongside it. Animal studies show that long-term use of PCP or ketamine can cause brain changes resembling those seen in people with schizophrenia [2], which is part of why a psychiatric assessment belongs in the first week rather than the fourth.
Physical. Sleep disruption, appetite change and fatigue are the ordinary background to stopping any heavily used substance. They are not specific to PCP and they are not what makes it distinctive.
Behavioral. Phencyclidine use disorder is a diagnosis in its own right in the DSM-5 [2]. The craving and the pull back toward use are the part of this that a treatment plan is built around, and the part that the first weeks decide.
What matters for a reader is the grouping rather than the list. The neurological and psychiatric columns are the ones that need clinical eyes on them.
The PCP withdrawal timeline, from the first day to the weeks after
The first day is governed by pharmacology, and the weeks after it are not. That is the shape of this timeline, and it is why a fixed schedule would be a fiction.
The StatPearls review of phencyclidine toxicity estimates the half-life at 21 hours, and says symptoms can last from several hours up to 48 hours depending on the dose [1]. Our own page on how long PCP stays in your system carries a different estimate, three days, from a 2007 study it names. Two attributed estimates are more honest here than one flat number. So the acute picture is measured in hours and days rather than weeks, and StatPearls puts the outside edge of the acute symptoms at 48 hours [1].
The drug itself lingers longer than the acute effects do. Federal treatment guidance gives urine detection periods for PCP of 2 to 7 days after acute use and up to 30 days with chronic use [5]. Our own page on how long PCP stays in your system gives up to five days for infrequent use, and the same up to 30 days for regular use. The two acute figures come from different tables and sit inside the same broad picture. What either means for one person depends on the dose and on the pattern of use [5]. The same appendix notes that substances are excreted at various rates, and that they accumulate in the body with continued use [5]. The cutoff the assay is set to matters too, and that is a question for whoever runs the test. A detection window is not a symptom timeline, but it tells you something useful: the body is still dealing with the substance after the obvious effects have gone.
Weeks one to four are where the fluctuation shows up. Because PCP is released from fat stores, recurrent symptoms can occur days to months after the last use [1]. A good week followed by a bad day is the expected pattern rather than a sign that something has gone wrong, and knowing that in advance is most of the value of reading this page.
Psychiatric symptoms follow their own clock. Where psychosis occurs it can persist for days to weeks [2], and that course is set by the person rather than by a protocol.
What makes one person’s experience worse than another’s
Four things separate a hard course from a manageable one, and only one of them is the drug.
The first is how much fat-stored drug there is to release. Because phencyclidine is fat-soluble and can be released from lipid stores days to months later [1], a long heavy pattern of use sets up a longer tail of recurring symptoms than an occasional one does.
The second is psychiatric history. Research suggests that PCP can make symptoms worse in people who have schizophrenia and can cause short-term episodes of psychosis [2]. Someone with an existing psychotic illness, or with a history of one in the family, is in a different risk band, and that belongs on the intake form.
The third is what else is being used. Alcohol and sedative withdrawal carry their own medical dangers, and when they are in the mix they set the level of care, not PCP. Prescribed medications belong in the same answer, which is why our guide to prescription drug addiction is worth reading before the intake call. Where they are in the mix, that is what an assessment weighs when it recommends a monitored setting.
The fourth is circumstance. Somewhere to stay, someone who knows what is happening, and a way to reach help if a bad episode arrives at two in the morning. Those are not clinical variables, but they decide more outcomes than any of the first three. Our explainer on levels of care sets out the five main levels of treatment.
Medical detox for PCP: what supervision adds
Supervision buys three things, and federal guidance names them directly: evaluation, stabilization, and fostering the person’s entry into treatment [3].
Evaluation is the part people undervalue. It establishes what is actually being used, what else is going on medically and psychiatrically, and which risks apply. Where a recurring episode of confusion or agitation might be met at home with alarm and a guess, a clinical setting meets it with a history and a set of observations.
Stabilization is the management of the acute picture. For PCP toxicity the published approach is environmental as much as pharmacological: placing the person in a calm environment such as a quiet room with the lights dimmed may be helpful [1]. That is difficult to reproduce at home and easy to reproduce in a unit.
The third component is the one that decides whether any of it lasts. TIP 45’s consensus panel takes special care to note that detoxification is not substance abuse treatment and rehabilitation [3]. A plan that stops at the end of detox is not a plan.
Where that happens depends on the assessment. Federal guidance sets out the settings in which withdrawal management occurs, from a physician’s office and ambulatory care through to medically managed intensive inpatient care [4]. The five levels it attaches to them are ASAM’s Adult Detoxification placement levels within Dimension 1, not the general treatment ladder [4]. Medical detox explains what the higher-intensity end of that looks like in practice.
Medications and supportive care used during PCP withdrawal
Neither NIDA’s page on hallucinogens and dissociative drugs [2] nor the StatPearls review of phencyclidine toxicity [1] names a medication approved to treat PCP withdrawal, the way methadone, buprenorphine and naltrexone are approved for opioid use disorder. What StatPearls describes instead is symptom-directed care [1].
For agitation during PCP toxicity, benzodiazepines are the preferred medication for chemical sedation, and they are also described as first-line for PCP-induced hypertension and seizures [1]. Hyperthermia in PCP toxicity comes from psychomotor agitation and can be treated with the same class [1]. Those are decisions made by a treating clinician with the person in front of them, which is why this page names no amount, no interval and no schedule.
Supportive care does the rest of the work. StatPearls puts the quiet, dimly lit environment in its treatment section and says it may be helpful [1], so it belongs in the plan rather than among the comforts. Monitoring matters because of the complications that can accompany PCP toxicity — rhabdomyolysis, hypoglycemia, seizures, hypertensive crisis, coma and trauma [1].
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.
Where a psychotic episode persists, psychiatric care is the relevant specialty, not addiction medicine alone [2]. Ask on the first call whether psychiatric assessment is part of the admission or a referral out, because the answer changes the shape of the first week. Our page on medication-assisted treatment explains where medication does and does not have an established role.
Protracted symptoms and months one to six
The long tail is the part of PCP that has no analogue in most other substances, and it is the reason to plan past the first month.
The mechanism is straightforward. Phencyclidine is fat-soluble, is stored in lipid tissue and can be released from it, and that release produces recurrent, fluctuating symptoms that can occur days to months after the initial use [1]. This is not a relapse and it is not imagination; it is pharmacokinetics.
The practical consequences are worth naming. A returning episode can be mistaken for a new exposure by an employer, a family member or a probation officer, and a urine test can stay positive for up to 30 days after chronic use [5]. Both of those are worth raising with a clinician in advance rather than explaining afterwards.
Psychiatric symptoms can also outlast the acute phase, with psychosis persisting days to weeks in some cases [2]. Where mood, sleep or thinking have not settled by the end of the first month, that is information for the treating team rather than a reason to stop treatment.
What months one to six should contain is ordinary and unglamorous: continuing care, a psychiatric review if one is warranted, and a written plan for what happens on a bad day. How long treatment takes sets out the usual shapes.
Treatment after PCP withdrawal: residential, PHP and IOP
Withdrawal management is the beginning of treatment, not a treatment in itself [3]. What follows is chosen from a ladder, and the assessment picks the rung.
Residential and inpatient care means living at the program while the day is structured around therapy, groups and clinical review. It is the usual recommendation where the home setting is where use happens, where psychiatric symptoms are unsettled, or where an earlier attempt at a lighter level did not hold.
A partial hospitalization program runs close to full clinical hours with the person sleeping at home or in supported housing. An intensive outpatient program runs fewer structured hours a week and is built around work and family commitments. Standard outpatient care is the lightest tier and is usually where the long work happens.
The therapy content is the same across those tiers; the intensity and the supervision change. NIDA describes cognitive-behavioral therapy, contingency management, motivational enhancement therapy and family therapy among the behavioral treatments for substance use disorders [7]. With no medication approved for PCP, those are what a program has to offer.
Cost is the objection that stops people at this point more often than clinical doubt does. Our pages on insurance coverage for rehab and what treatment costs explain the vocabulary before the verification call, and how admission works covers the sequence from the first phone call to arrival. We name only our own facilities, and our list of treatment centers names our campuses and the states they are in. For anything beyond ours, you can also start at FindTreatment.gov.
Frequently Asked Questions
How long does PCP withdrawal last? There is no fixed length, and any page that gives you one is guessing. The acute effects are measured in hours. The StatPearls review of phencyclidine toxicity estimates the half-life at 21 hours, and says symptoms can last from several hours up to 48 hours depending on the dose. The difficulty is the tail. Because the drug is fat-soluble and released from fat stores, recurrent symptoms can occur days to months after the last use.
Can I stop PCP on my own? That is a question for a clinician who knows your history, not for a website. Two things decide it: whether alcohol or sedatives are also in the picture, because those carry their own medical dangers when stopped, and whether psychiatric symptoms are present, since PCP can cause psychosis that persists for days to weeks. An assessment settles both in a single appointment, and it is the cheapest step in the whole process.
What is the worst day of PCP withdrawal? There is no reliable worst day, and that is the unusual thing about PCP. Rather than a single peak, the published picture is one of recurrent, fluctuating symptoms that can occur days to months after use, because the drug is released from fat stores over time. Expect an uneven course instead of a curve, and treat a bad day several weeks in as normal rather than as failure.
Is there medication for PCP withdrawal? No medication approved specifically for PCP withdrawal is named on either source this page rests on. NIDA’s page on hallucinogens and dissociative drugs does not name one, and neither does the StatPearls review of phencyclidine toxicity. Care is directed at symptoms instead. Benzodiazepines are described as the preferred medication for chemical sedation in PCP toxicity and as first-line for PCP-induced hypertension and seizures, and StatPearls says placing the person in a calm environment such as a quiet room with the lights dimmed may be helpful. If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.
Does insurance cover detox? Usually in part, and the detail is in your plan rather than in the carrier’s name. Federal parity law stops a plan that covers substance use disorder benefits from applying tighter financial requirements or treatment limits to them than it applies to medical and surgical benefits, and prior authorization rules count among those limits. The scope is worth knowing: it applies to non-federal governmental plans with more than 50 employees, to group health plans of private employers with more than 50 employees, and to the individual market. Plans from small employers are not covered directly; they get comparable protection through the Affordable Care Act’s essential health benefits requirement.
Sources
- Journey, J. D., & Bentley, T. P. (2023). Phencyclidine Toxicity. StatPearls, NCBI Bookshelf, National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK507865/
- National Institute on Drug Abuse. Hallucinogens and Dissociative Drugs. National Institutes of Health. https://nida.nih.gov/research-topics/hallucinogens
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment — Chapter 1, Overview, Essential Concepts, and Definitions in Detoxification. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64119/
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment — Chapter 2, Settings, Levels of Care, and Patient Placement. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64109/
- Center for Substance Abuse Treatment. (2006). Substance Abuse: Clinical Issues in Intensive Outpatient Treatment — Appendix B, Exhibit B-1: Urine Toxicology Detection Periods for Different Substances. Treatment Improvement Protocol (TIP) Series No. 47, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64092/
- Centers for Medicare & Medicaid Services. The Mental Health Parity and Addiction Equity Act (MHPAEA). https://www.cms.gov/marketplace/private-health-insurance/mental-health-parity-addiction-equity
- National Institute on Drug Abuse. Treatment and Recovery. Drugs, Brains, and Behavior: The Science of Addiction. National Institutes of Health. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.
Author
Chief Medical Officer,
The Recovery Village
